Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KraneShares Electric Vehicles and Future Mobility — how do they compare? ACADIA Pharmaceuticals Inc. trades at $28.43 (market cap $5.07B), while KraneShares Electric Vehicles and Future Mobility trades at $30.87. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| ACAD | KARS | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.45 | $38.01 |
52-Week Low | $20.06 | $25.59 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $28.38, down 3.5% over the past day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with $0.18 EPS versus $0.07 expected, and raised its 2026 revenue outlook. Revenue growth has accelerated from $517M in 2022 to $1.07B in 2025, with net income turning positive in 2024 and reaching $391M in 2025.
The outlook remains positive with 70% analyst buy ratings and a $33.89 consensus price target, though risks include high RSI levels suggesting overbought conditions and dependence on key drug trials. Near-term catalysts include Phase 2 data for remlifanserin in Alzheimer's psychosis, expected by October 2026.
KARS trades at $30.95, up 0.85% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum with an ADX of 72.14 (June 2026, Reuters) indicating a robust trend, though RSI suggests potential overbought conditions. Recent news highlights global EV sales growth, particularly in Europe and China, supporting the sector's positive outlook.
The EV sector's expansion offers growth potential, but KARS faces risks from competitive pressures and regulatory shifts. Analyst sentiment is mixed, with technical strength countered by valuation concerns. Investors should weigh sector tailwinds against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
